Research statistics

Bremelanotide research: publications and trials

What has been published on Bremelanotide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Bremelanotide works or is safe. For what it is and what the studies found, see the Bremelanotide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

66

Since 2003

Publications in 2026 so far

6

Through November 15, 2026

Human clinical research

25.4%

16 of 63 classified

Registered clinical trials

10

ClinicalTrials.gov

Randomized controlled trials

14

Publications reporting an RCT in people

Systematic reviews and meta-analyses

5

Preclinical studies

15.9%

5 animal · 3 in vitro · 2 computational

Records that only mention it

50

Not counted above

Status in the library: FDA-approved. Groups: Melanocortin agonists. 3 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Bremelanotide publications by year and evidence

2003, Human clinical research: 1 of 12004, Human clinical research: 2 of 52004, Preclinical (animal, in vitro, computational): 1 of 52004, Reviews and meta-analyses: 2 of 52005, Human clinical research: 1 of 12006, Human clinical research: 1 of 22006, Other and not yet classified: 1 of 22007, Preclinical (animal, in vitro, computational): 1 of 52007, Reviews and meta-analyses: 3 of 52007, Other and not yet classified: 1 of 52008, Human clinical research: 1 of 22008, Reviews and meta-analyses: 1 of 22011, Reviews and meta-analyses: 1 of 12013, Reviews and meta-analyses: 1 of 22013, Other and not yet classified: 1 of 22014, Reviews and meta-analyses: 2 of 22016, Human clinical research: 1 of 22016, Other and not yet classified: 1 of 22017, Human clinical research: 2 of 32017, Other and not yet classified: 1 of 32018, Reviews and meta-analyses: 1 of 12019, Human clinical research: 3 of 72019, Reviews and meta-analyses: 2 of 72019, Other and not yet classified: 2 of 72020, Preclinical (animal, in vitro, computational): 2 of 42020, Reviews and meta-analyses: 2 of 42021, Human clinical research: 1 of 72021, Preclinical (animal, in vitro, computational): 1 of 72021, Reviews and meta-analyses: 4 of 72021, Other and not yet classified: 1 of 72022, Human clinical research: 3 of 52022, Reviews and meta-analyses: 2 of 52023, Reviews and meta-analyses: 1 of 12024, Preclinical (animal, in vitro, computational): 1 of 22024, Reviews and meta-analyses: 1 of 22025, Preclinical (animal, in vitro, computational): 3 of 72025, Reviews and meta-analyses: 4 of 72026 (to date), Preclinical (animal, in vitro, computational): 1 of 62026 (to date), Reviews and meta-analyses: 4 of 62026 (to date), Other and not yet classified: 1 of 6Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified02468200320072014201920232026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
200310001
200421205
200510001
200610012
200701315
200810102
201100101
201300112
201400202
201610012
201720013
201800101
201930227
202002204
202111417
202230205
202300101
202401102
202503407
2026 (to date)01416

Study types

Review26
Randomized controlled trial14
Editorial, letter or other6
Animal study5
In vitro study3
Systematic review3
Not yet classified3
Computational study2
Meta-analysis2
Other clinical trial1
Observational human study1

Research areas

From MeSH major topics. A paper can be in several areas.

Reproductive and sexual health49
Neurological and mental health37
Endocrinology3
Dermatology2
Metabolic health2
Obesity and weight management2
Oncology2
Antimicrobial and infectious disease1
Cardiovascular1
Longevity and aging1
Tissue repair1

Registered clinical trials

5 of 9 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 9 · Active, not recruiting: 1
Phase 1: 1 · Phase 2: 4 · Phase 3: 3 · Phase 4: 2

TrialStatusPhaseStartedResults
Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast MilkNCT06867835 · 10 enrolledCompletedPhase 42025-07—
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of ObesityNCT06565611 · 108 enrolledActive, not recruitingPhase 22024-08—
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseaseNCT05709444 · 16 enrolledCompletedPhase 22022-12—
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)NCT04943068 · 193 enrolledCompletedPhase 32021-05—
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire DisorderNCT04179734 · 40 enrolledCompletedPhase 42019-10Posted
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With ZofranNCT03973047 · 228 enrolledCompletedPhase 12019-06—
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderNCT02338960 · 714 enrolledCompletedPhase 32015-01Posted
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderNCT02333071 · 723 enrolledCompletedPhase 32014-12Posted
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire DisorderNCT01382719 · 612 enrolledCompletedPhase 22011-06Posted
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)NCT00425256CompletedPhase 22006-02—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.

    Journal of minimally invasive gynecology · June 19, 2025 · Meta-analysis · cited 6 times

    PMID 40543759 · DOI 10.1016/j.jmig.2025.06.004 · Reviews and meta-analyses

  2. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.

    Journal of sex research · March 7, 2021 · Meta-analysis · cited 17 times

    PMID 33678061 · DOI 10.1080/00224499.2021.1885601 · Reviews and meta-analyses

  3. Peptides for male sexual dysfunction: a systematic review of emerging evidence.

    The journal of sexual medicine · November 1, 2026 · Systematic review · cited 0 times

    PMID 43002584 · DOI 10.1093/jsxmed/qdag338 · Reviews and meta-analyses

  4. Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.

    Frontiers in medicine · May 22, 2026 · Systematic review · cited 0 times · open access

    PMID 42254382 · DOI 10.3389/fmed.2026.1789809 · Reviews and meta-analyses

  5. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.

    The Annals of pharmacotherapy · January 1, 2020 · Systematic review · cited 47 times

    PMID 31893927 · DOI 10.1177/1060028019899152 · Reviews and meta-analyses

  6. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.

    Diabetes, obesity & metabolism · March 15, 2022 · Randomized controlled trial · cited 16 times · open access

    PMID 35170192 · DOI 10.1111/dom.14672 · Human clinical research

  7. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.

    Journal of women's health (2002) · February 25, 2022 · Randomized controlled trial · cited 9 times

    PMID 35230162 · DOI 10.1089/jwh.2021.0225 · Human clinical research

  8. Safety Profile of Bremelanotide Across the Clinical Development Program.

    Journal of women's health (2002) · February 1, 2022 · Randomized controlled trial · cited 11 times

    PMID 35147466 · DOI 10.1089/jwh.2021.0191 · Human clinical research

  9. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.

    Journal of women's health (2002) · February 3, 2021 · Randomized controlled trial · cited 12 times

    PMID 33538638 · DOI 10.1089/jwh.2020.8460 · Human clinical research

  10. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.

    Obstetrics and gynecology · November 1, 2019 · Randomized controlled trial · cited 294 times · open access

    PMID 31599840 · DOI 10.1097/aog.0000000000003500 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.

    Obstetrics and gynecology · November 1, 2019 · Randomized controlled trial · cited 294 times · open access

    PMID 31599840 · DOI 10.1097/aog.0000000000003500 · Human clinical research

  2. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.

    Obstetrics and gynecology · November 1, 2019 · Observational human study · cited 198 times · open access

    PMID 31599847 · DOI 10.1097/aog.0000000000003514 · Human clinical research

  3. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist.

    Proceedings of the National Academy of Sciences of the United States of America · June 28, 2004 · Animal study · cited 129 times · open access

    PMID 15226502 · DOI 10.1073/pnas.0400491101 · Animal studies

  4. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.

    International journal of impotence research · February 1, 2004 · Randomized controlled trial · cited 128 times

    PMID 14963471 · DOI 10.1038/sj.ijir.3901139 · Human clinical research

  5. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.

    The journal of sexual medicine · July 1, 2006 · Randomized controlled trial · cited 116 times

    PMID 16839319 · DOI 10.1111/j.1743-6109.2006.00268.x · Human clinical research

Latest publications

  1. Peptides for male sexual dysfunction: a systematic review of emerging evidence.

    The journal of sexual medicine · November 1, 2026 · Systematic review · cited 0 times

    PMID 43002584 · DOI 10.1093/jsxmed/qdag338 · Reviews and meta-analyses

  2. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review.

    Sexual medicine reviews · September 1, 2026 · Review · cited 0 times

    PMID 42862021 · DOI 10.1093/sxmrev/qeag078 · Reviews and meta-analyses

  3. Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling.

    Analytical methods : advancing methods and applications · August 20, 2026 · Computational study · cited 0 times

    PMID 42485063 · DOI 10.1039/d6ay01098a · Computational studies

  4. Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.

    Frontiers in medicine · May 22, 2026 · Systematic review · cited 0 times · open access

    PMID 42254382 · DOI 10.3389/fmed.2026.1789809 · Reviews and meta-analyses

  5. Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?

    Journal of clinical psychopharmacology · April 10, 2026 · Not yet classified · cited 0 times

    PMID 41960633 · DOI 10.1097/jcp.0000000000002179 · Not yet classified

  6. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

    Frontiers in aging · April 7, 2026 · Review · cited 4 times · open access

    PMID 42021992 · DOI 10.3389/fragi.2026.1790247 · Reviews and meta-analyses

  7. Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies.

    Expert review of clinical pharmacology · October 24, 2025 · Review · cited 1 times

    PMID 41088800 · DOI 10.1080/17512433.2025.2573780 · Reviews and meta-analyses

  8. Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.

    Journal of minimally invasive gynecology · June 19, 2025 · Meta-analysis · cited 6 times

    PMID 40543759 · DOI 10.1016/j.jmig.2025.06.004 · Reviews and meta-analyses

  9. A biodegradable suction patch for sustainable transbuccal peptide delivery.

    Journal of controlled release : official journal of the Controlled Release Society · June 11, 2025 · Animal study · cited 7 times · open access

    PMID 40513668 · DOI 10.1016/j.jconrel.2025.113947 · Animal studies

  10. FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach.

    Turkish journal of biology = Turk biyoloji dergisi · April 7, 2025 · Computational study · cited 0 times · open access

    PMID 40678415 · DOI 10.55730/1300-0152.2741 · Computational studies

Browse all 66 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Bremelanotida; Bremelanotide; Bremelanotidum; PT-141; Vyleesi

((TITLE_ABS:"Bremelanotida" OR CHEM:"Bremelanotida") OR (TITLE_ABS:"Bremelanotide" OR CHEM:"Bremelanotide") OR (TITLE_ABS:"Bremelanotidum" OR CHEM:"Bremelanotidum") OR (TITLE_ABS:"PT-141" OR CHEM:"PT-141" OR TITLE_ABS:"PT141" OR CHEM:"PT141") OR (TITLE_ABS:"Vyleesi" OR CHEM:"Vyleesi")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Bremelanotide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/bremelanotide